Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients

Trial Profile

A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients

Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 18 Sep 2018

At a glance

  • Drugs Antithrombin alfa (Primary)
  • Indications Antithrombin III deficiency
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 26 Mar 2018 Planned initiation date changed from 1 Jan 2018 to 1 Jun 2018.
    • 09 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top